Aumolertinib

Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer.^[1] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).^[2]

Aumolertinib

Clinical data
Trade names	Ameile
Other names	Almonertinib; HS-10296
ATC code	L01EB11 (WHO)
Legal status
Legal status	CN: Rx-only
Identifiers
IUPAC name N-[5-[[4-(1-Cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
CAS Number	1899921-05-1
PubChem CID	121280087
IUPHAR/BPS	11136
DrugBank	DB16640
ChemSpider	75535991
UNII	T4RS462G19
ChEMBL	ChEMBL4761468
Chemical and physical data
Formula	C30H35N7O2
Molar mass	525.657 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC
InChI InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34) Key:DOEOECWDNSEFDN-UHFFFAOYSA-N

In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy.^[3][4]